Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Frontiers of Medicine ; (4): 426-439, 2018.
Artículo en Inglés | WPRIM | ID: wpr-771289

RESUMEN

Tumor microenvironment (TME) is comprised of cellular and non-cellular components that exist within and around the tumor mass. The TME is highly dynamic and its importance in different stages of cancer progression has been well recognized. A growing body of evidence suggests that TME also plays pivotal roles in cancer treatment responses. TME is significantly remodeled upon cancer therapies, and such change either enhances the responses or induces drug resistance. Given the importance of TME in tumor progression and therapy resistance, strategies that remodel TME to improve therapeutic responses are under developing. In this review, we provide an overview of the essential components in TME and the remodeling of TME in response to anti-cancer treatments. We also summarize the strategies that aim to enhance therapeutic efficacy by modulating TME.


Asunto(s)
Humanos , Antineoplásicos , Farmacología , Resistencia a Medicamentos , Estadificación de Neoplasias , Neoplasias , Quimioterapia , Patología , Resultado del Tratamiento , Microambiente Tumoral , Fisiología
2.
Endocrinology and Metabolism ; : 206-212, 2016.
Artículo en Inglés | WPRIM | ID: wpr-126434

RESUMEN

Bone metastasis is a frequent occurrence in breast cancer, affecting more than 70% of late stage cancer patients with severe complications such as fracture, bone pain, and hypercalcemia. The pathogenesis of osteolytic bone metastasis depends on cross-communications between tumor cells and various stromal cells residing in the bone microenvironment. Several growth factor signaling pathways, secreted micro RNAs (miRNAs) and exosomes are functional mediators of tumor-stromal interactions in bone metastasis. We developed a functional genomic approach to systemically identified molecular pathways utilized by breast cancer cells to engage the bone stroma in order to generate osteolytic bone metastasis. We showed that elevated expression of vascular cell adhesion molecule 1 (VCAM1) in disseminated breast tumor cells mediates the recruitment of pre-osteoclasts and promotes their differentiation to mature osteoclasts during the bone metastasis formation. Transforming growth factor β (TGF-β) is released from bone matrix upon bone destruction, and signals to breast cancer to further enhance their malignancy in developing bone metastasis. We furthered identified Jagged1 as a TGF-β target genes in tumor cells that engaged bone stromal cells through the activation of Notch signaling to provide a positive feedback to promote tumor growth and to activate osteoclast differentiation. Substantially change in miRNA expression was observed in osteoclasts during their differentiation and maturation, which can be exploited as circulating biomarkers of emerging bone metastasis and therapeutic targets for the treatment of bone metastasis. Further research in this direction may lead to improved diagnosis and treatment strategies for bone metastasis.


Asunto(s)
Humanos , Biomarcadores , Matriz Ósea , Neoplasias de la Mama , Mama , Diagnóstico , Exosomas , Fracturas Óseas , Hipercalcemia , MicroARNs , Metástasis de la Neoplasia , Osteoblastos , Osteoclastos , Células del Estroma , Factor de Crecimiento Transformador beta , Factores de Crecimiento Transformadores , Molécula 1 de Adhesión Celular Vascular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA